Practice
Featured experience
Chime $993.6 million IPO
The shares are listed on the Nasdaq Global Select Market
Cipher Mining 300 MW, $5.5 billion lease agreement with Amazon Web Services
We advised Cipher Mining on the transaction
Diameter Capital Partners $4.5 billion fundraise for its third dislocation fund
We advised Diameter on the transaction
Banco Santander $12.2 billion acquisition of Webster Bank
We are advising Banco Santander on the transaction
Golden Wheel Tiandi $170 million high-yield notes offering
Davis Polk advised the initial purchasers in connection with a $170 million Regulation S offering by Golden Wheel Tiandi…
Ocumension Therapeutics HK$1.55 billion IPO and HKEX listing
Davis Polk advised the underwriters in the initial public offering of Ocumension Therapeutics on the Hong Kong Stock…
Ocumension Therapeutics HK$1.55 billion IPO and HKEX listing
Davis Polk advised the underwriters in the initial public offering of Ocumension Therapeutics on the Hong Kong Stock…
Sumitomo Mitsui Financial Group $3 billion notes offering
Davis Polk advised Sumitomo Mitsui Financial Group, Inc. on its SEC-registered takedown offering of senior total loss…
Ucommune $769 million merger with Orisun Acquisition
Davis Polk is advising Ucommune Group Holdings Ltd. on its merger with Orisun Acquisition Corp. The transaction values the…
Shenzhen Hepalink Pharmaceutical Group HK$4.05 billion IPO
Davis Polk advised Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in connection with its initial public offering and…
Sumitomo Mitsui Financial Group $3 billion notes offering
Davis Polk advised Sumitomo Mitsui Financial Group, Inc. on its SEC-registered takedown offering of senior total loss…
Ucommune $769 million merger with Orisun Acquisition
Davis Polk is advising Ucommune Group Holdings Ltd. on its merger with Orisun Acquisition Corp. The transaction values the…
Outotec Oyj combination with Metso’s minerals business
Davis Polk advised Outotec Oyj as to U.S. law in connection with the demerger by Metso Corporation’s minerals business by…
Shenzhen Hepalink Pharmaceutical Group HK$4.05 billion IPO
Davis Polk advised Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in connection with its initial public offering and…